Aeon Global Health 10-Q 9 Nov 18 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2018	Oct. 25, 2018
Document Information [Line Items]
Entity Registrant Name	Aeon Global Health Corp.
Entity Central Index Key	885,074
Trading Symbol	aghc
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		7,383,706
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2018	Jun. 30, 2018
Current assets
Cash and cash equivalents	$ 569,694	$ 723,352
Accounts receivable, net	2,701,110	2,507,304
Inventory, net	407,878	453,129
Prepaid expenses and other current assets	79,405	54,058
Total current assets	3,758,087	3,737,843
Property and equipment, net	1,292,990	1,421,097
Other assets
Deferred tax asset	5,816,315	5,816,315
Total assets	10,867,392	10,975,255
Current liabilities
Accounts payable	1,644,229	1,436,897
Accrued expenses	2,029,564	2,082,591
Accrued commissions	459,211	608,405
Accrued dividends	85,941	984,979
Accrued income taxes payable	515,667	515,667
Accrued interest notes payable	151,527	155,257
Deferred rent	204,452	194,628
Notes payable	1,698,169	3,049,651
Derivative liabilities	815,001	1,323,625
Total current liabilities	7,603,761	10,351,700
Deferred rent	157,498	135,001
Related party notes payable	1,415,449
Deferred Taxes Payable
Total liabilities	9,176,708	10,486,701
Commitments and contingencies
Shareholders’ equity
Preferred stock, $.10 par value; 5,000,000 shares authorized, Series D, 605,000 shares and Series E 25,000 shares issued and outstanding at September 30, 2018, and June 30, 2018, respectively	63,000	63,000
Common stock, $.001 par value; 190,000,000 shares authorized, 7,383,706 and 7,249,370 shares issued and outstanding on September 30, 2018, and June 30, 2018 , respectively	25,714	25,579
Additional paid-in capital	46,600,419	45,089,337
(Accumulated deficit) retained earnings	(44,998,449)	(44,689,362)
Total shareholders’ equity	1,690,684	488,554
Total liabilities and shareholders’ equity	$ 10,867,392	$ 10,975,255

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2018	Jun. 30, 2018
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	190,000,000	190,000,000
Common stock, shares issued (in shares)	7,383,706	7,249,370
Common stock, shares outstanding (in shares)	7,383,706	7,249,370
Series D Convertible Preferred Stock [Member]
Preferred stock, shares issued (in shares)	605,000	605,000
Preferred stock, shares outstanding (in shares)	605,000	605,000
Series E Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 30
Preferred stock, shares issued (in shares)	25,000	25,000
Preferred stock, shares outstanding (in shares)	25,000	25,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Net revenues
Net revenues	$ 3,741,190	$ 3,358,052
Operating expenses
Cost of revenues	1,456,650	1,128,576
Selling, general and administrative	2,176,977	3,072,428
Share based compensation	69,400	68,785
Depreciation and amortization	125,777	222,584
Total operating expenses	3,828,804	4,492,373
Operating loss	(87,614)	(1,134,321)
Other (expense) income
Interest	(48,736)	(27,349)
Change in fair value of derivative liabilities	50,966	73,291
Other	(128,822)	(38,144)
	(126,592)	7,798
Loss before provision for income taxes	(214,206)	(1,126,523)
Provision for income taxes	(9,166)
Net loss	(223,372)	(1,126,523)
Less: preferred dividends	(85,715)	(84,550)
Net loss available to common shareholders	$ (309,087)	$ (1,211,073)
Loss per share:
Basic loss per common share (in dollars per share)	$ (0.04)	$ (0.17)
Diluted loss per common share (in dollars per share)	$ (0.04)	$ (0.17)
Weighted average number of common shares outstanding
Basic (in shares)	7,365,723	7,249,370
Diluted (in shares)	7,365,723	7,249,370
Fees for Service [Member]
Net revenues
Net revenues	$ 3,537,631	$ 3,110,382
Hosted Software Service [Member]
Net revenues
Net revenues	199,009	243,020
Telehealth Product and Service [Member]
Net revenues
Net revenues	$ 4,550	$ 4,650

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - 3 months ended Sep. 30, 2018 - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Jun. 30, 2018	630,000	7,249,370
Balance at Jun. 30, 2018	$ 63,000	$ 25,579	$ 45,089,337	$ (44,689,362)	$ 488,554
Share-based compensation expense			69,400		69,400
Preferred common stock dividends (in shares)		134,336
Preferred common stock dividends		$ 135	984,622	(85,715)	899,042
Related party debt restructuring			457,060		457,060
Net income (loss)				(223,372)	(223,372)
Balance (in shares) at Sep. 30, 2018	630,000	7,383,706
Balance at Sep. 30, 2018	$ 63,000	$ 25,714	$ 46,600,419	$ (44,998,449)	$ 1,690,684

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash Flow from operating activities
Net income (loss)	$ (223,372)	$ (1,126,523)
Adjustments to reconcile net income (loss) to net cash provided by operating activities
Change in fair value of derivative liabilities	(50,966)	(73,291)
Depreciation and amortization	125,777	222,584
Share based compensation	69,400	68,785
Changes in assets and liabilities
Accounts receivable	(193,806)	205,469
Inventory	45,251	(29,863)
Prepaid expenses and other current assets	(25,347)	(27,378)
Accounts payable	207,332	(472,295)
Accrued expenses	62,746	615,322
Accrued commissions	(202,993)	108,515
Deferred rent	32,320
Net cash used in operating activities	(153,658)	(508,675)
Cash flows from investing activities
Disposal of fixed assets		33
Net cash provided by investing activities		33
Net decrease in cash, cash equivalents, and restricted cash	(153,658)	(508,642)
Cash, cash equivalents, and restricted cash at beginning of year	723,352	1,242,458
Cash, cash equivalents, and restricted cash at end of period	569,694	733,816
Cash and cash equivalents	569,694	733,816
Restricted cash included in restricted bank deposit
Supplemental disclosure of cash paid for:
Income taxes paid	9,224	76,316
Non-cash investing and financing activities
Non-cash preferred dividends	85,715	84,550
Preferred dividends settled in common stock	$ 984,622

Note 1 - Description of Busines

Note 1 - Description of Business, Reverse Merger and Liquidity	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Business AEON Global Health Corp. (“AGHC” or the “Company”) and its subsidiaries primarily provides an array of clinical testing services to health care professionals through its wholly-owned subsidiary, Peachstate Health Management, LLC d/b/a AEON Clinical Laboratories (“AEON”). The Company also continues to provide its legacy secure web-based revenue cycle management applications and telehealth products and services that enable healthcare organizations to increase revenues, improve productivity, reduce costs, coordinate care for patients and enhance related administrative and clinical workflows and compliance with regulatory requirements. Web-based services are delivered as Software as a Service (SaaS) to customers interfacing seamlessly with billing, information and records management systems. Going Concern As of the filing date of this Quarterly Report on Form 10 6 $3,113,618 $1,698,169 March 20, 2020 $2.0 $1,415,449 September 30, 2018 June 30, 2020. $81,000, twelve no not The Company's capital requirements have been and will continue to be significant and it is expending significant amounts of capital to develop, promote and market its services. The Company’s available cash and cash equivalents as of September 30, 2018 $570,000 $3,846,000. 10 $457,000 $1,200,000. The Company does not may may may may may may may not third no Management has concluded that due to the conditions described above, there is substantial doubt about the entity’s ability to continue as a going concern. We have evaluated the significance of the conditions in relation to our ability to meet our obligations and believe that our current cash balance and future cash receipts from revenue will provide sufficient capital to continue operations through fiscal 2019. not no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies The Company's condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and following the requirements of the Securities and Exchange Commission ("SEC") for interim reporting. As permitted under those rules certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These interim financial statements have been prepared on the same basis as the Company's annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company's financial information. These interim results are not June 30, 2019 June 30, 2018, 2018 10 The balance sheet as of June 30, 2018 not Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most sensitive accounting estimates affecting the financial statements are revenue recognition, the allowance for doubtful accounts, depreciation of long-lived assets, fair value of intangible assets and goodwill, amortization of intangible assets, income taxes and associated deferrals and valuation allowances, commitments and contingencies and measurement of derivative liabilities. Accounts Receivable, Net Accounts receivable represent customer obligations due under normal trade terms, net of allowance for doubtful accounts. The allowance for doubtful accounts reflects our best estimate of probable losses inherent in the accounts receivable balance. We determine the allowance based on known troubled accounts, historical experience and other currently available evidence. The allowance for doubtful accounts was approximately $960,000 $942,000 September 30, 2018 June 30, 2018, Fair Value Measurements The Company follows Accounting Standards Codification (“ASC”) 820 10, "Fair Value Measurements and Disclosures" 820 10 820 10 three three 820 10 Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, Level 3 Pricing inputs that are generally unobservable input and not The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lower priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one 3. Concentrations of Credit Risk The Company maintains its cash in bank deposit accounts which, at times, may September 30, 2018 June 30, 2018, $320,000 $473,000 not At September 30, 2018, one $1,116,000. 31% September 30, 2018. Income Taxes The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in tax laws or rates. The effect on deferred taxes and liabilities of a change in tax rates will be recognized as income or expense in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. Management considers the likelihood of changes by taxing authorities in its filed income tax returns and recognizes a liability for or discloses potential changes that management believes are more likely than not not Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation. Recent Accounting Pronouncements In May 2014, 2014 09, Revenue from Contracts with Customers 606 3 10 no three September 30, 2018. In February 2016, 2016 02, Leases , ” twelve December 15, 2018, first 2020 not not In August 2016, 2016 15, Statement of Cash Flows (Topic 230 July 1, 2018 no In May 2017, 217 09, “Compensation-Stock Compensation (Topic 718 December 15, 2017. not 2019 In July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no no July 1, 2019. In December 2017, No. 118, 740, “Income Taxes ”, December 22,2017, No. 118 December 22, 2017. No. 118 2018 In August 2018, 2018 13. 820 820 3 July 1, 2020.

Note 3 - Revenue Recognition

Note 3 - Revenue Recognition	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3. Revenue Recognition The Company commenced recognizing revenue in accordance with the provisions of ASC 606, Revenue from Contracts with Customers July 1, 2018 95% 93% three September 30, 2018 2017 not 5% 7% three September 30, 2018. The following are descriptions of the AEON business’ portfolios: Healthcare Insurers Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules. Revenues consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical denial and collection experience and the terms of the Company’s contractual arrangements. Adjustments to the allowances, based on actual receipts from the commercial payers, are recorded upon settlement. Collection of consideration the Company expects to receive is normally a function of providing complete and correct billing information to the healthcare insurers within the various filing deadlines and typically occurs within 30 60 Government Payers Reimbursements from government payers are based on fee-for-services schedules set by government authorities, including traditional Medicare and Medicaid. Revenues consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical denial and collection experience and other factors. Adjustments to the allowances, based on accrual receipts from the government payers, are recorded upon settlement. Client Payers Client payers include physicians, hospitals, accountable care organizations, integrated delivery networks, employers and other commercial laboratories and institutions for which services are performed on a wholesale basis and are billed based on negotiated fee schedules. Collection of consideration the Company expects to receive typically occurs within 60 90 Patients Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients. Insured patients (includes coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers. Collection of billings from patients is subject to credit risk and ability of the patients to pay. Revenues consist of amounts billed net of discounts provided to uninsured patients. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive from patients, which considers historical collection experience and other factors including current market conditions. Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement. Telehealth The Company enters into contracts with customers that may The approximate percentage of net revenue by type of customer was as follows: Three Months Ended September 30, 2018 Healthcare Insurers 46.9 % Government Payers 23.5 % Client Payers 24.4 % Patient 0.2 % Telehealth 5.0 % Net revenues 100.0 %

Note 4 - Inventory

Note 4 - Inventory	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Inventory Disclosure [Text Block]	4 . Inventory Inventory consists of the following: September 30, June 30, 2018 2018 Laboratory testing supplies $ 407,878 $ 453,129 Total inventory $ 407,878 $ 453,129

Note 5 - Income Taxes

Note 5 - Income Taxes	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	5. Income Taxes The Company's effective tax rate for the three September 30, 2018 2017 3.4% 0.0%, three September 30, 2018, 21% At September 30, 2018, $40,699,000. $34,883,000 not $5,816,000.

Note 6 - Related Party Notes Pa

Note 6 - Related Party Notes Payable	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Short-term Debt [Text Block]	6 . Related Party Notes Payable September 30, 2018 June 30, 2018 Interest rate Note Interest rate Principal per annum Payable per annum Secured $ 1,056,875 5% interest paid annually $ 1,056,875 5% interest paid annually 641,294 5% interest paid annually 641,294 5% interest paid annually 1,415,449 7.5% interest paid annually 255,417 5% interest paid annually 591,613 5% interest paid annually 504,452 5% interest paid annually Total $ 3,113,618 Total $ 3,049,651 The principal amount listed above is principal only and does not $49,000 July 1, 2018 September 30, 2018. Fiscal 2018 Exchange Transaction On March 27, 2018, $500,000, Note Amendment Transaction In the Note Amendment Transaction, the holders (the "Senior Holders") of the outstanding principal amount of $2,545,199 twelve March 20, 2019 $1.20 2,120,999 not 1 $255,417 $591,613 825,144 $2.07 $1.22 September 30, 2018 $202,000, not March 20, 2019 Note Exchange Transaction In connection with the Note Amendment Transaction, on March 27, 2018, $500,000, $504,452, March 27, 2018. The Additional Senior Note is the same, in all material respects, as the Senior Notes described above in the Note Amendment Transaction and was convertible into shares of the Company's Common Stock at an initial conversion price of $1.20. 420,376 may first In accordance with ASC 470 50, Debt - Modifications and Extinguishments $247,539 Fiscal 2019 Restructuring Transaction Note Restructuring Transaction On July 19, 2018, As a condition to the effectiveness of the Settlement Agreement, the parties agreed to restructure the loans previously made to the Company by Mr. Roshan and Optimum Ventures, LLC, (together the “Lenders”) and to exchange the existing Senior Notes held by them for a new senior credit instrument pursuant to which they will provide up to $2.0 July 19, 2018 ( “July $1,351,482 Pursuant to the July $2.0 not 7.5% June 30, 2020. The Grid Notes are on parity with an outstanding principal amount of $1,698,169 first may 110% The Grid Notes were issued in consideration of the exchange of (i) an aggregate principal amount of $759,869 $591,613 $1,100,000 $900,000. September 30, 2018 $1,415,449. July 19, 2018. In accordance with ASC 470 50, Debt - Modifications and Extinguishments zero September 30, 2018. In connection with the Note Restructuring Transaction, the Company entered into a consent and amendment agreement with the Convertible Note Holders to obtain their consent to the issuance of the Grid Notes. In consideration thereof, the Company and Convertible Note Holders also agree to extend the maturity date of the Senior Convertible Notes for a period of one March 20, 2020 March 20, 2017,

Note 7 - Equity

Note 7 - Equity	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7 . Equity Preferred Stock As of September 30, 2018, 25,000 187,500 $4.00 not $30.00 one 5% September 30, 2018 $9,349 As of September 30, 2018, 605,000 619,154 $9.77139 may not $10.00 June 2016. 5% September 30, 2018, $76,366 The Company's preferred stock takes precedence over Common Stock but ranks below debt in the event of liquidation. In addition, the Series D Convertible Preferred Stock ranks above the Series E Convertible Preferred Stock. Earnings per Share FASB ASC Topic 260, Earnings per Share three September 30, 2018, Three Months Ended September 30, 2018 2017 Basic earnings (loss) per share Net loss $ (223,372) $ (1,126,523 ) Preferred stock dividends (85,715 ) (84,550 ) Net loss available to common shareholders after preferred stock dividends $ (309,087) $ (1,211,073 ) Weighted average shares used in the computation of basic earnings per share 7,365,723 7,249,370 Loss per share - basic $ (0.04) $ (0.17 ) Dilutive earnings (loss) per share Loss available to common shareholders $ (309,087) $ (1,211,073 ) Weighed average shares used in the computation of diluted loss per share 7,365,723 7,249,370 Shares used in the computation of diluted loss per share 7,365,723 7,249,370 Loss per share - diluted $ (0.04) (0.17 ) Common Stock Warrants A schedule of common stock warrant activity for the three September 30, 2018 Warrant Activity Number of Shares Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding June 30, 2018 3,458,826 $ 3.65 3.41 $ - Issued - Expired (61,112 ) $ 11.69 - $ - Outstanding September 30, 2018 3,397,714 $ 3.25 3.30 $ - Exercisable, September 30, 2018 3,397,714 $ 3.25 3.47 $ - Due to the adjustment of the conversion price of the New Senior Notes, the exercise price of outstanding warrants to purchase an aggregate of 825,144 $2.07 $1.22

Note 8 - Share-based Compensati

Note 8 - Share-based Compensation	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	8 . Share-Based Compensation Stock option activity under the Company's stock option plans for employees and non-executive directors for the three September 30, 2018 Employees Information Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding June 30, 2018 265,346 $ 7.08 6.55 Granted - - - Expired/Forfeited (29,167 ) 3.39 - Outstanding September 30, 2018 236,179 7.54 6.13 Exercisable September 30, 2018 139,751 $ 11.81 4.21 Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Non-Executive Director Information Options Price Life (Years) Value Outstanding June 30, 2018 545,059 $ 3.08 7.75 $ - Granted 5,001 0.67 9.93 300 Expired/forfeited - - - Outstanding and exercisable September 30, 2018 550,060 $ 3.04 7.54 $ 300 Share based compensation for the three September 30, 2018 2017 $69,400 $69,000 Restricted stock unit activity under the Company's restricted stock unit plans for employees and non-executive directors for the three September 30, 2018 Number of RSUs Weighted Average Grant Date Fair Value Outstanding June 30, 2018 752,391 $ 1.31 Granted - - Expired/Forfeited (37,000 ) 1.19 Outstanding September 30, 2018 715,391 $ 1.32

Note 9 - Earn-out Merger Consid

Note 9 - Earn-out Merger Consideration	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Earn-out Stock Compensation Plan [Text Block]	9. Earn-Out Merger Consideration Pursuant to the Amended and Restated Agreement and Plan of Merger dated January 26, 2016, May 31, 2016 December 2016 ( three December 31, 2018 ( “2018 85% four December 31,2019 “2019 90% 70,000,000 Subsequently, in connection with the Merger, the parties expressed differences of opinion on the interpretation of certain provisions of the Merger Agreement, the calculation of the number of shares of common stock issued pursuant to the initial tranches of the Earn-out under the Merger Agreement, and the assumption of income tax liabilities for undistributed income earned by AEON prior to the Merger. The Company has also incurred negative cash flow for the calendar years 2016 2017, $760,000 $591,613, March 20, 2019 $1.20 1,126,235 zero The Company, AEON and the Former Members reached an agreement to resolve these matters and entered into the Settlement Agreement in order to: (i) provide a source of working capital to the Company to sustain operations and reduce the additional dilution which could have been caused by the conversion of the Loans; (ii) remove the uncertainty as to the number of shares which may 2018 2019 70,000,000 1,200,000 2018 2019 The parties also resolved all interpretative issues relating to the Merger Agreement and clarified the amount and terms of the Earn-outs as described below. With respect to 2018 2018 $21,483,749 three December 31, 2018. 2018 October 1, 2019, December 31, 2018, 3,000,000 not 2018 three December 31, 2018 75% 2018 October 1, 2019, December 31, 2018, 2,250,000 With respect to the 2019 2019 $32,600,530 four December 31, 2019. 2019 three December 31,2019, 4,000,000 2019 December 31, 2019 75% 2019 three December 31, 2019, 3,000,000 The parties also agreed that if the 2019 not 2018 2018 2018 2018 75% 2018 The Company also agreed that in consideration of the restructuring of the consideration due to the Former Members under the Merger Agreement, it shall issue an aggregate of 2,500,000 pro rata February 28, 2019. As additional consideration to the Company under the Settlement Agreement, the Former Members agreed: (i) to relinquish all demand registration rights; (ii) that the arrangements set forth in the Settlement Agreement fully resolved any and all claims arising out of the Merger Agreement and the transactions contemplated thereby; and (iii) to a general release of claims as against the Company.

Note 10 - Fair Value Measuremen

Note 10 - Fair Value Measurements and Other Financial Instruments	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	10 . Fair Value Measurements and Other Financial Instruments The carrying amounts of the Company's financial assets and liabilities, such as cash, accounts receivable, inventory, prepaid expenses, and other current assets, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments. In connection with the issuance of a convertible promissory notes as discussed in Note 6, $1,351,482 July 19, 2018 6 not The Company's Level 3 2011 2015. three September 30, 2016 $1,698,169 The Company utilized the following assumptions in valuing the derivative conversion features: Exercise Price $ 1.20 - $ 1.22 Risk free interest rate 2.32 % - 2.93 % Expected volatility 130 % - 200 % Remaining Term (years) 0.47 - 4.82 Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis The fair value of the Company's financial instruments, using the fair value hierarchy under U.S. GAAP detailed in "Fair Value Measurements" 2, The Company uses Level 3 3 The following tables provide a summary of the changes in fair value, including net transfers in and/or out, of all financial assets / (liabilities) measured at the fair value on a recurring basis using significant unobservable inputs during the three September 30, 2018. Convertible Warrants Notes Total Balance - June 30, 2018 $ 505,069 $ 818,556 $ 1,323,625 Change in fair value of derivative liabilities (64,333 ) (444,291) (508,624) Balance - September 30, 2018 $ 440,736 $ 374,265 $ 815,001 Fair value Level 1 Level 2 Level 3 June 30, 2018 Derivative liabilities $ 1,323,625 $ - $ - $ 1,323,625 September 30, 2018 Derivative liabilities $ 815,001 $ - $ - $ 815,001 Of the $508,624 $457,000 July 19, 2018. 6 For the three September 30, 2018 2017, $509,000 $773,000

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	11 . Commitments and Contingencies In the case captioned Medlogic, LLC and Malena F. Badon v . Peachstate Health M anagement, LLC, et al. 15 th No.: 2015 0151 not Prior to the completion of the merger, AT&T provided various communication services and equipment to the Company, including facsimile lines. AT&T has claimed that the Company owes approximately $500,000 no September 30, 2018. Regarding the termination of the Company’s relationship with certain executives, including the former Chief Executive Officer of Authentidate Holding Corp., O’Connell Benjamin, the Company has been reviewing its severance obligations and the vesting of post-termination provisions. The Company believes it has accrued all related severance costs as of September 30, 2018 June 22, 2016 $341,620 October 30, 2017, no On Mar 3, 2017, 1996, 23, 2017 may, not The Company was the defendant in an action captioned Cogmedix, Inc. v. Authentidate Holding Corp. No.: 1685CV013188. September 6, 2016, December 6, 2013, $227,061, February 15, 2018, $320,638 October 17, 2018, 9 $149,996 June 2019. The Company, its Chief Executive Officer, and certain yet identified persons are defendants in a case captioned Carlotta Miraflor v. Peachstate Health Management, LLC d/b/a Aeon Global Health, et al. October 4, 2017 No.: 5:17 02046 January 3, 2018 July 2017, The Company is the defendant in the case captioned Healthy Practice Solutions, LLC v. Peachstate Health Management, LLC, No.: 18 000042, not On September 15, 2015, six $135,000 first $148,000 18 th 27 th 36 th $121,000 July 2017, first 2018. not The Company is also subject to claims and litigation arising in the ordinary course of business. Our management considers that any liability from any reasonably foreseeable disposition of such claims and litigation, individually or in the aggregate, would not The Company has entered into various agreements by which we may may may third not not September 30, 2018, not

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	12 . Related Party Transactions Except as disclosed herein, the Company has not 5% July 1, 2017. AEON leases its facilities from Centennial Properties of Georgia, LLC under a lease agreement commencing April 2014, January 20, 2016. 12 March 2026. $46,500 $60,000. first three September 2018 2017 $77,000 $144,000, The Company holds certain related party notes payable to certain shareholders and its Chief Executive Officer, as detailed in Note 6. $49,000 $32,000, three September 30, 2018 2017, The Company entered into a lease agreement with Hanif A. ("Sonny") Roshan (the "landlord") for a residential premises at 5455 30517 one January 1, 2018 December 31, 2018 $7,500 first 3% $22,500 $22,500 three September 30, 2018 2017. Certain of the Company's affiliates, including members of its senior management and board, as well as their respective family members and other affiliates, have relationships and agreements among themselves as well as with the Company and its affiliates, that create the potential for both real, as well as perceived, conflicts of interest. These include certain with which the Company does business. The Company does business with Kemah Palms, an entity that is majority owned by the Company's Chairman and CEO, Hanif Roshan. AEON generated approximately $10,000 2018. On September 18, 2018, no 10% three An entity affiliated with the Company’s Chief Executive Officer extended a personal loan of $500,000

Note 13 - Segment Information

Note 13 - Segment Information	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1 3 . Segment Information The Company is operated as two Selected financial information related to the Company's segments is presented below: Authentidate AEON Total Three Months ended September 30, 2018 Net revenues $ 203,559 $ 3,537,631 $ 3,741,190 Cost of revenues 39,883 1,416,767 1,456,650 Operating expenses 189,841 3,638,963 3,828,804 Operating income (loss) 13,718 (101,332 ) (87,614 ) Net income (loss) 78,793 (302,165) (223,372 ) Three months ended September 30, 2017 Net revenues $ 247,670 $ 3,110,382 $ 3,358,052 Cost of revenues 55,127 1,073,449 1,128,576 Operating expenses 873,385 3,618,988 4,492,373 Operating income (loss) (628,715 ) (505,606 ) (1,134,321 ) Net income (loss) (520,947 ) (605,576) (1,126,523 ) September 30, 2018 Total assets $ 5,967,666 4,899,726 $ 10,867,392 June 30, 2018 Total Assets $ 7,532,512 $ 3,442,743 $ 10,975,255

Note 14 - Subsequent Events

Note 14 - Subsequent Events	3 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	14. The Company was the defendant in an action captioned Cogmedix, Inc. v. Authentidate Holding Corp. No.: 1685CV013188. September 6, 2016, December 6, 2013, $227,061, February 15, 2018, $320,638 October 17, 2018, 9 $149,996 June 2019.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most sensitive accounting estimates affecting the financial statements are revenue recognition, the allowance for doubtful accounts, depreciation of long-lived assets, fair value of intangible assets and goodwill, amortization of intangible assets, income taxes and associated deferrals and valuation allowances, commitments and contingencies and measurement of derivative liabilities.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts Receivable, Net Accounts receivable represent customer obligations due under normal trade terms, net of allowance for doubtful accounts. The allowance for doubtful accounts reflects our best estimate of probable losses inherent in the accounts receivable balance. We determine the allowance based on known troubled accounts, historical experience and other currently available evidence. The allowance for doubtful accounts was approximately $960,000 $942,000 September 30, 2018 June 30, 2018,
Revenue Recognition, Policy [Policy Text Block]	Fair Value Measurements The Company follows Accounting Standards Codification (“ASC”) 820 10, "Fair Value Measurements and Disclosures" 820 10 820 10 three three 820 10 Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, Level 3 Pricing inputs that are generally unobservable input and not The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lower priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one 3.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk The Company maintains its cash in bank deposit accounts which, at times, may September 30, 2018 June 30, 2018, $320,000 $473,000 not At September 30, 2018, one $1,116,000. 31% September 30, 2018.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in tax laws or rates. The effect on deferred taxes and liabilities of a change in tax rates will be recognized as income or expense in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. Management considers the likelihood of changes by taxing authorities in its filed income tax returns and recognizes a liability for or discloses potential changes that management believes are more likely than not not
Reclassification, Policy [Policy Text Block]	Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, 2014 09, Revenue from Contracts with Customers 606 3 10 no three September 30, 2018. In February 2016, 2016 02, Leases , ” twelve December 15, 2018, first 2020 not not In August 2016, 2016 15, Statement of Cash Flows (Topic 230 July 1, 2018 no In May 2017, 217 09, “Compensation-Stock Compensation (Topic 718 December 15, 2017. not 2019 In July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no no July 1, 2019. In December 2017, No. 118, 740, “Income Taxes ”, December 22,2017, No. 118 December 22, 2017. No. 118 2018 In August 2018, 2018 13. 820 820 3 July 1, 2020.

Note 3 - Revenue Recognition (T

Note 3 - Revenue Recognition (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended September 30, 2018 Healthcare Insurers 46.9 % Government Payers 23.5 % Client Payers 24.4 % Patient 0.2 % Telehealth 5.0 % Net revenues 100.0 %

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, June 30, 2018 2018 Laboratory testing supplies $ 407,878 $ 453,129 Total inventory $ 407,878 $ 453,129

Note 6 - Related Party Notes _2

Note 6 - Related Party Notes Payable (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Debt [Table Text Block]	September 30, 2018 June 30, 2018 Interest rate Note Interest rate Principal per annum Payable per annum Secured $ 1,056,875 5% interest paid annually $ 1,056,875 5% interest paid annually 641,294 5% interest paid annually 641,294 5% interest paid annually 1,415,449 7.5% interest paid annually 255,417 5% interest paid annually 591,613 5% interest paid annually 504,452 5% interest paid annually Total $ 3,113,618 Total $ 3,049,651

Note 7 - Equity (Tables)

Note 7 - Equity (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, 2018 2017 Basic earnings (loss) per share Net loss $ (223,372) $ (1,126,523 ) Preferred stock dividends (85,715 ) (84,550 ) Net loss available to common shareholders after preferred stock dividends $ (309,087) $ (1,211,073 ) Weighted average shares used in the computation of basic earnings per share 7,365,723 7,249,370 Loss per share - basic $ (0.04) $ (0.17 ) Dilutive earnings (loss) per share Loss available to common shareholders $ (309,087) $ (1,211,073 ) Weighed average shares used in the computation of diluted loss per share 7,365,723 7,249,370 Shares used in the computation of diluted loss per share 7,365,723 7,249,370 Loss per share - diluted $ (0.04) (0.17 )
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant Activity Number of Shares Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding June 30, 2018 3,458,826 $ 3.65 3.41 $ - Issued - Expired (61,112 ) $ 11.69 - $ - Outstanding September 30, 2018 3,397,714 $ 3.25 3.30 $ - Exercisable, September 30, 2018 3,397,714 $ 3.25 3.47 $ -

Note 8 - Share-based Compensa_2

Note 8 - Share-based Compensation (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Employees Information Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding June 30, 2018 265,346 $ 7.08 6.55 Granted - - - Expired/Forfeited (29,167 ) 3.39 - Outstanding September 30, 2018 236,179 7.54 6.13 Exercisable September 30, 2018 139,751 $ 11.81 4.21 Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Non-Executive Director Information Options Price Life (Years) Value Outstanding June 30, 2018 545,059 $ 3.08 7.75 $ - Granted 5,001 0.67 9.93 300 Expired/forfeited - - - Outstanding and exercisable September 30, 2018 550,060 $ 3.04 7.54 $ 300
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	Number of RSUs Weighted Average Grant Date Fair Value Outstanding June 30, 2018 752,391 $ 1.31 Granted - - Expired/Forfeited (37,000 ) 1.19 Outstanding September 30, 2018 715,391 $ 1.32

Note 10 - Fair Value Measurem_2

Note 10 - Fair Value Measurements and Other Financial Instruments (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Exercise Price $ 1.20 - $ 1.22 Risk free interest rate 2.32 % - 2.93 % Expected volatility 130 % - 200 % Remaining Term (years) 0.47 - 4.82
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Convertible Warrants Notes Total Balance - June 30, 2018 $ 505,069 $ 818,556 $ 1,323,625 Change in fair value of derivative liabilities (64,333 ) (444,291) (508,624) Balance - September 30, 2018 $ 440,736 $ 374,265 $ 815,001
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]	Fair value Level 1 Level 2 Level 3 June 30, 2018 Derivative liabilities $ 1,323,625 $ - $ - $ 1,323,625 September 30, 2018 Derivative liabilities $ 815,001 $ - $ - $ 815,001

Note 13 - Segment Information (

Note 13 - Segment Information (Tables)	3 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Authentidate AEON Total Three Months ended September 30, 2018 Net revenues $ 203,559 $ 3,537,631 $ 3,741,190 Cost of revenues 39,883 1,416,767 1,456,650 Operating expenses 189,841 3,638,963 3,828,804 Operating income (loss) 13,718 (101,332 ) (87,614 ) Net income (loss) 78,793 (302,165) (223,372 ) Three months ended September 30, 2017 Net revenues $ 247,670 $ 3,110,382 $ 3,358,052 Cost of revenues 55,127 1,073,449 1,128,576 Operating expenses 873,385 3,618,988 4,492,373 Operating income (loss) (628,715 ) (505,606 ) (1,134,321 ) Net income (loss) (520,947 ) (605,576) (1,126,523 ) September 30, 2018 Total assets $ 5,967,666 4,899,726 $ 10,867,392 June 30, 2018 Total Assets $ 7,532,512 $ 3,442,743 $ 10,975,255

Note 1 - Description of Busin_2

Note 1 - Description of Business, Reverse Merger and Liquidity (Details Textual) - USD ($)	Nov. 07, 2018	Oct. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017
Short-term Debt, Total			$ 1,415,449
Cash and Cash Equivalents, at Carrying Value, Ending Balance			569,694	723,352	$ 733,816
Working Capital (Deficit)			3,846,000
Subsequent Event [Member]
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 0	$ 457,000
Estimated Monthly Operational Requirement	1,200,000
Subsequent Event [Member] | Grid Notes [Member]
Debt Instrument, Face Amount	2,000,000
Secured Debt, Total	1,415,449
Subsequent Event [Member] | Secured Notes Maturing on June 15, 2018 [Member]
Debt Instrument, Face Amount	81,000
Subsequent Event [Member] | Subordinated Secured Note Payable [Member] | Former Chief Financial Officer [Member] | Accrued Expenses [Member]
Due to Related Parties, Total	1,698,169
Secured Convertible Note Payable [Member]
Short-term Debt, Total				$ 3,049,651
Debt Instrument, Face Amount			$ 3,113,618
Secured Convertible Note Payable [Member] | Subsequent Event [Member]
Short-term Debt, Total	$ 3,113,618

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended
	Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)
Allowance for Doubtful Accounts Receivable, Current, Ending Balance	$ 960,000	$ 942,000
Cash, Uninsured Amount	320,000	$ 473,000
One Customer [Member]
Accounts Receivable, Net, Total	$ 1,116,000
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number of Major Customers	1
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]
Concentration Risk, Percentage	31.00%

Note 3 - Revenue Recognition (D

Note 3 - Revenue Recognition (Details Textual)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Percentage of Revenues	100.00%
Lab Test [Member]
Percentage of Revenues	95.00%	93.00%
Telehealth [Member]
Percentage of Revenues	5.00%	7.00%

Note 3 - Revenue Recognition -

Note 3 - Revenue Recognition - Revenues by Type of Customers (Details)	3 Months Ended
	Sep. 30, 2018
Percentage of net revenue	100.00%
Healthcare Insurers [Member]
Percentage of net revenue	46.90%
Government Payers [Member]
Percentage of net revenue	23.50%
Client Payers [Member]
Percentage of net revenue	24.40%
Patient [Member]
Percentage of net revenue	0.20%
Telehealth [Member]
Percentage of net revenue	5.00%

Note 4 - Inventory - Inventory

Note 4 - Inventory - Inventory (Details) - USD ($)	Sep. 30, 2018	Jun. 30, 2018
Laboratory testing supplies	$ 407,878	$ 453,129
Total inventory	$ 407,878	$ 453,129

Note 5 - Income Taxes (Details

Note 5 - Income Taxes (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2019
Effective Income Tax Rate Reconciliation, Percent, Total	3.40%	0.00%
Deferred Tax Assets, Net, Total	$ 40,699,000
Deferred Tax Assets, Valuation Allowance, Total	34,883,000
Deferred Tax Assets, Operating Loss Carryforwards, Total	$ 5,816,000
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%

Note 6 - Related Party Notes _3

Note 6 - Related Party Notes Payable (Details Textual)	Jul. 19, 2018USD ($)	Jun. 30, 2018USD ($)$ / shares	Mar. 27, 2018USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Mar. 26, 2018$ / shares
Interest Payable, Current		$ 155,257		$ 151,527
Short-term Debt, Total				1,415,449
New Notes Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			825,144
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 1.22		$ 2.07
Note Restructuring Transaction [Member] | AEON Global Health Corp [Member] | Lenders [Member]
Debt Agreement, Maximum Borrowing Capacity	$ 2,000,000
Chief Executive Officer [Member] | AEON Global Health Corp [Member]
Short-term Debt, Total		$ 760,000
Chief Executive Officer [Member] | Grid Notes [Member] | AEON Global Health Corp [Member]
Debt Instrument, Face Amount	1,100,000
Short-term Debt, Total	759,869
Optimum Ventures, LLC [Member] | AEON Global Health Corp [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 1.20
Debt Instrument, Convertible, Number of Equity Instruments		1,126,235
Short-term Debt, Total		$ 591,613
Optimum Ventures, LLC [Member] | Grid Notes [Member] | AEON Global Health Corp [Member]
Debt Instrument, Face Amount	900,000
Short-term Debt, Total	591,613			1,415,449
Lenders [Member]
Debt Instrument, Face Amount	1,351,482
Lenders [Member] | Grid Notes [Member]
Debt Instrument, Face Amount	$ 2,000,000
Debt Instrument, Interest Rate, Stated Percentage	7.50%
Lenders [Member] | Grid Notes [Member] | AEON Global Health Corp [Member]
Debt Instrument, Redemption Price, Percentage	110.00%
Promissory Notes [Member] | Chief Executive Officer [Member]
Debt Instrument, Face Amount			$ 500,000
Secured Convertible Note Payable [Member]
Debt Instrument, Face Amount				3,113,618
Short-term Debt, Total		$ 3,049,651
Paid-in-Kind Interest				0
Secured Convertible Note Payable [Member] | New Notes [Member]
Debt Instrument, Face Amount			$ 2,545,199
Debt Instrument, Convertible, Conversion Price | $ / shares			$ 1.20
Debt Instrument, Convertible, Number of Equity Instruments			2,120,999
Interest Payable, Current				$ 202,000
Gain (Loss) on Extinguishment of Debt, Total			$ (247,539)
Secured Convertible Note Payable [Member] | Additional Senior Note [Member]
Debt Instrument, Face Amount			$ 504,452
Debt Instrument, Convertible, Conversion Price | $ / shares			$ 1.20
Debt Instrument, Convertible, Number of Equity Instruments			420,376
Secured Convertible Note Payable [Member] | Original Notes [Member] | AEON Global Health Corp [Member]
Debt Instrument, Face Amount	$ 1,698,169
Secured Convertible Note Payable [Member] | Chief Executive Officer [Member] | New Notes [Member]
Debt Instrument, Face Amount			$ 255,417
Secured Convertible Note Payable [Member] | Optimum Ventures, LLC [Member] | New Notes [Member]
Debt Instrument, Face Amount			$ 591,613

Note 6 - Related Party Notes _4

Note 6 - Related Party Notes Payable - Related Party Notes Payable (Details) - USD ($)	Sep. 30, 2018	Jun. 30, 2018
Related party notes payable	$ 1,415,449
Secured Convertible Note Payable [Member]
Related party notes payable, principal	3,113,618
Related party notes payable		$ 3,049,651
Secured Convertible Note Payable [Member] | Lender One [Member]
Related party notes payable, principal	$ 1,056,875
Debt instrument, stated percentage	5.00%	5.00%
Related party notes payable		$ 1,056,875
Secured Convertible Note Payable [Member] | Lender Two [Member]
Related party notes payable, principal	$ 641,294
Debt instrument, stated percentage	5.00%	5.00%
Related party notes payable		$ 641,294
Secured Convertible Note Payable [Member] | Lender Three [Member]
Related party notes payable, principal	$ 1,415,449
Debt instrument, stated percentage	7.50%	5.00%
Related party notes payable		$ 255,417
Secured Convertible Note Payable [Member] | Lender Four [Member]
Related party notes payable, principal
Debt instrument, stated percentage		5.00%
Related party notes payable		$ 591,613
Secured Convertible Note Payable [Member] | Lender Five [Member]
Related party notes payable, principal
Debt instrument, stated percentage		5.00%
Related party notes payable		$ 504,452

Note 7 - Equity (Details Textua

Note 7 - Equity (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 27, 2018	Mar. 26, 2018
Preferred Stock, Par or Stated Value Per Share	$ 0.10	$ 0.10
New Notes Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			825,144
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.22	$ 2.07
Series E Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance	25,000	25,000
Convertible Preferred Stock, Aggregate Shares Issued upon Conversion	187,500
Convertible Preferred Stock, Conversion Price	$ 4
Preferred Stock, Par or Stated Value Per Share	$ 30
Preferred Stock, Period Following Issuance Date to Initiate Redemption	1 year
Preferred Stock, Dividend Rate, Percentage	5.00%
Dividends Payable	$ 9,349
Series D Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance	605,000	605,000
Convertible Preferred Stock, Aggregate Shares Issued upon Conversion	619,154
Convertible Preferred Stock, Conversion Price	$ 9.77139
Preferred Stock, Dividend Rate, Percentage	5.00%
Dividends Payable	$ 76,366
Preferred Stock, Redemption Price Per Share	$ 10

Note 7 - Equity - Earnings Per

Note 7 - Equity - Earnings Per Share (Details) - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Basic earnings (loss) per share
Net loss	$ (223,372)	$ (1,126,523)
Preferred stock dividends	(85,715)	(84,550)
Net loss available to common shareholders after preferred stock dividends	$ (309,087)	$ (1,211,073)
Weighted average shares used in the computation of basic earnings per share (in shares)	7,365,723	7,249,370
Loss per share - basic (in dollars per share)	$ (0.04)	$ (0.17)
Dilutive earnings (loss) per share
Loss available to common shareholders	$ (309,087)	$ (1,211,073)
Weighed average shares used in the computation of diluted loss per share (in shares)	7,365,723	7,249,370
Shares used in the computation of diluted loss per share (in shares)	7,365,723	7,249,370
Loss per share - diluted (in dollars per share)	$ (0.04)	$ (0.17)

Note 7 - Equity - Warrant Activ

Note 7 - Equity - Warrant Activity (Details) - Warrant [Member] - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2018	Jun. 30, 2018
Warrants outstanding (in shares)	3,458,826
Warrants outstanding, weighted average exercise price per share (in dollars per share)	$ 3.65
Warrants outstanding, weighted average remaining contractual life (Year)	3 years 109 days	3 years 149 days
Warrants outstanding, aggregate intrinsic value
Warrants issued (in shares)
Warrants issued, weighted average exercise price per share (in dollars per share)
Warrants expired (in shares)	(61,112)
Warrants expired, weighted average exercise price per share (in dollars per share)	$ 11.69
Warrants outstanding (in shares)	3,397,714	3,458,826
Warrants outstanding, weighted average exercise price per share (in dollars per share)	$ 3.25	$ 3.65
Warrants exercisable (in shares)	3,397,714
Warrants exercisable, weighted average exercise price per share (in dollars per share)	$ 3.25
Warrants exercisable, weighted average remaining contractual life (Year)	3 years 171 days
Warrants exercisable, aggregate intrinsic value

Note 8 - Share-based Compensa_3

Note 8 - Share-based Compensation (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Allocated Share-based Compensation Expense, Total	$ 69,400	$ 69,000

Note 8 - Share-based Compensa_4

Note 8 - Share-based Compensation - Stock Option Activity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2018	Jun. 30, 2018
Employees [Member]
Outstanding, beginning of period (in shares)	265,346
Outstanding, weighted average exercise price (in dollars per share)	$ 7.08
Outstanding, average remaining contractual life (Year)	6 years 47 days	6 years 200 days
Number of options granted (in shares)
Granted, weighted average exercise price (in dollars per share)
Granted, average remaining contractual life (Year)
Number of options expired/forfeited (in shares)	(29,167)
Expired/forfeited, weighted average exercise price (in dollars per share)	$ 3.39
Expired/forfeited, average remaining contractual life (Year)
Outstanding, end of period (in shares)	236,179	265,346
Outstanding, weighted average exercise price (in dollars per share)	$ 7.54	$ 7.08
Exercisable (in shares)	139,751
Exercisable, weighted average exercise price (in dollars per share)	$ 11.81
Exercisable, average remaining contractual life (Year)	4 years 76 days
Non-Executives [Member]
Outstanding, beginning of period (in shares)	545,059
Outstanding, weighted average exercise price (in dollars per share)	$ 3.08
Outstanding, average remaining contractual life (Year)	7 years 197 days	7 years 273 days
Number of options granted (in shares)	5,001
Granted, weighted average exercise price (in dollars per share)	$ 0.67
Granted, average remaining contractual life (Year)	9 years 339 days
Number of options expired/forfeited (in shares)
Expired/forfeited, weighted average exercise price (in dollars per share)
Expired/forfeited, average remaining contractual life (Year)
Outstanding, end of period (in shares)	550,060	545,059
Outstanding, weighted average exercise price (in dollars per share)	$ 3.04	$ 3.08
Outstanding, aggregate intrinsic value	$ 300
Granted, aggregate intrinsic value	300
Expired/forfeited, aggregate intrinsic value

Note 8 - Share-based Compensa_5

Note 8 - Share-based Compensation - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Sep. 30, 2018$ / sharesshares
Number of RSUs outstanding (in shares) | shares	752,391
RSUs outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 1.31
Number of RSUs granted (in shares) | shares
RSUs granted, weighted average grant date fair value (in dollars per share) | $ / shares
Number of RSUs expired/forfeited (in shares) | shares	(37,000)
RSUs expired/forfeited, weighted average grant date fair value (in dollars per share) | $ / shares	$ 1.19
Number of RSUs outstanding (in shares) | shares	715,391
RSUs outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 1.32

Note 9 - Earn-out Merger Cons_2

Note 9 - Earn-out Merger Consideration (Details Textual) - USD ($)	Jul. 19, 2018	Jun. 30, 2018	Sep. 30, 2018
Short-term Debt, Total			$ 1,415,449
AEON Global Health Corp [Member]
Number of Shares of the Company’s Common Stock Issued Presented as Percentage of Issued and Outstanding Shares If EBITDA Level Is Achieved for Three Years		85.00%
Number of Shares of the Company’s Common Stock Issued Presented as Percentage of Issued and Outstanding Shares If EBITDA Level Is Achieved for Four Years		90.00%
Number of Shares Issuable upon Achievement of Earnout	1,200,000	70,000,000
The 2018 Earnout Presented as Amount of EBITDA for Three Years	$ 21,483,749
Fixed Numbers of Shares Issuable If the 2018 Earnout Achieved	3,000,000
Percentage of 2018 Earnout Target Required for Three Years	75.00%
Fixed Numbers of Shares Issuable If 2018 EBITDA for Three Years Is Met	$ 2,250,000
The 2019 Earnout Presented as Amount of EBITDA for Three Years	$ 32,600,530
Fixed Numbers of Shares Issuable If the 2019 Earnout Achieved	4,000,000
Percentage of 2019 Earnout Target Required for Three Years	75.00%
Fixed Numbers of Shares Issuable If 2019 EBITDA for Three Years Is Met	3,000,000
Number of Additional Shares Issuable in Consideration of Restructuring	2,500,000
AEON Global Health Corp [Member] | Chief Executive Officer [Member]
Short-term Debt, Total		$ 760,000
AEON Global Health Corp [Member] | Optimum Ventures, LLC [Member]
Short-term Debt, Total		$ 591,613
Debt Instrument, Convertible, Conversion Price		$ 1.20
Debt Instrument, Convertible, Number of Equity Instruments		1,126,235

Note 10 - Fair Value Measurem_3

Note 10 - Fair Value Measurements and Other Financial Instruments (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Jul. 19, 2018
Convertible Notes Payable, Total	$ 1,698,169
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	(508,624)	$ (773,000)
Adjustment to Additional Paid in Capital, Related Party Debt Restructuring	$ 457,060
Lenders [Member]
Debt Instrument, Face Amount			$ 1,351,482

Note 10 - Fair Value Measurem_4

Note 10 - Fair Value Measurements and Other Financial Instruments - Valuation Techniques (Details)	Sep. 30, 2018yr
Minimum [Member] | Measurement Input, Exercise Price [Member]
Derivative valuation assumption	1.2
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Derivative valuation assumption	0.0232
Minimum [Member] | Measurement Input, Price Volatility [Member]
Derivative valuation assumption	1.3
Minimum [Member] | Measurement Input, Expected Term [Member]
Derivative valuation assumption	0.47
Maximum [Member] | Measurement Input, Exercise Price [Member]
Derivative valuation assumption	1.22
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Derivative valuation assumption	0.0293
Maximum [Member] | Measurement Input, Price Volatility [Member]
Derivative valuation assumption	2
Maximum [Member] | Measurement Input, Expected Term [Member]
Derivative valuation assumption	4.82

Note 10 - Fair Value Measurem_5

Note 10 - Fair Value Measurements and Other Financial Instruments - Summary in Changes in Fair Value (Details) - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Balance, beginning of period	$ 1,323,625
Change in fair value of derivative liabilities	(508,624)	$ (773,000)
Balance, end of period	815,001
Warrant [Member]
Balance, beginning of period	505,069
Change in fair value of derivative liabilities	(64,333)
Balance, end of period	440,736
Convertible Notes [Member]
Balance, beginning of period	818,556
Change in fair value of derivative liabilities	(444,291)
Balance, end of period	$ 374,265

Note 10 - Fair Value Measurem_6

Note 10 - Fair Value Measurements and Other Financial Instruments - Derivative Liabilities (Details) - USD ($)	Sep. 30, 2018	Jun. 30, 2018
Derivative liabilities	$ 815,001	$ 1,323,625
Fair Value, Inputs, Level 1 [Member]
Derivative liabilities
Fair Value, Inputs, Level 2 [Member]
Derivative liabilities
Fair Value, Inputs, Level 3 [Member]
Derivative liabilities	$ 815,001	$ 1,323,625

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual)	Oct. 17, 2018USD ($)	Feb. 15, 2018USD ($)	Sep. 06, 2016USD ($)	Jun. 22, 2016USD ($)	Sep. 15, 2015USD ($)	Sep. 30, 2018USD ($)
Offices in New Jersey [Member]
Lessee, Operating Lease, Term of Contract					6 years
Offices in New Jersey [Member] | Letter of Credit [Member]
Repayments of Debt					$ 121,000
Offices in New Jersey [Member] | Minimum [Member]
Operating Leases, Yearly Rent Expense					135,000
Offices in New Jersey [Member] | Maximum [Member]
Operating Leases, Yearly Rent Expense					$ 148,000
Alleged Amount Owed to AT&T [Member]
Loss Contingency, Damages Sought, Value						$ 500,000
Severance Compensation Arbitration Filed by Former CEO [Member]
Loss Contingency, Damages Sought, Value				$ 341,620
Cogmedix, Inc. v. Authentidate Holding Corp [Member]
Loss Contingency, Damages Sought, Value			$ 227,061
Litigation Settlement, Amount Awarded to Other Party		$ 320,638
Cogmedix, Inc. v. Authentidate Holding Corp [Member] | Subsequent Event [Member]
Litigation Settlement, Amount Awarded to Other Party, Number of Monthly Installments	9
Litigation Settlement, Amount Awarded to Other Party, Monthly Installments	$ 149,996

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - USD ($)	Sep. 18, 2018	Jan. 01, 2017	Jan. 20, 2016	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018
Interest Expense, Related Party				$ 49,000	$ 32,000
Centennial Properties of Georgia, LLC [Member]
Shared Services Agreement, Term	3 years
Kemah Palms [Member]
Revenue from Related Parties						$ 10,000
Entity Affiliated with Chief Executive Officer [Member]
Due from Related Parties, Total				500,000
Facilities Leased [Member] | Centennial Properties of Georgia, LLC [Member]
Lessee, Operating Lease, Term of Contract			12 years
Operating Leases, Rent Expense, Net, Total				77,000	144,000
Facilities Leased [Member] | Centennial Properties of Georgia, LLC [Member] | Minimum [Member]
Operating Leases, Monthly Rent Expense			$ 46,500
Facilities Leased [Member] | Centennial Properties of Georgia, LLC [Member] | Maximum [Member]
Operating Leases, Monthly Rent Expense			$ 60,000
Residential Premises Leased [Member] | Hanif A. Roshan [Member]
Lessee, Operating Lease, Term of Contract		1 year
Operating Leases, Monthly Rent Expense		$ 7,500
Operating Leases, Rent Expense, Net, Total				$ 22,500	$ 22,500
Operating Leases, Increase in Rent Expense Upon Each Renewal		3.00%

Note 13 - Segment Information_2

Note 13 - Segment Information (Details Textual)	3 Months Ended
	Sep. 30, 2018
Number of Operating Segments	2

Note 13 - Segment Information -

Note 13 - Segment Information - Selected Financial Information (Details) - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018
Net revenues	$ 3,741,190	$ 3,358,052
Cost of revenues	1,456,650	1,128,576
Operating expenses	3,828,804	4,492,373
Operating income (loss)	(87,614)	(1,134,321)
Net income (loss)	(223,372)	(1,126,523)
Total assets	10,867,392		$ 10,975,255
Web-based Software [Member]
Net revenues	203,559	247,670
Cost of revenues	39,883	55,127
Operating expenses	189,841	873,385
Operating income (loss)	13,718	(628,715)
Net income (loss)	78,793	(520,947)
Total assets	5,967,666		7,532,512
Laboratory Testing Services [Member]
Net revenues	3,537,631	3,110,382
Cost of revenues	1,416,767	1,073,449
Operating expenses	3,638,963	3,618,988
Operating income (loss)	(101,332)	(505,606)
Net income (loss)	(302,165)	$ (605,576)
Total assets	$ 4,899,726		$ 3,442,743

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details Textual) - Cogmedix, Inc. v. Authentidate Holding Corp [Member]	Oct. 17, 2018USD ($)	Feb. 15, 2018USD ($)	Sep. 06, 2016USD ($)
Loss Contingency, Damages Sought, Value			$ 227,061
Litigation Settlement, Amount Awarded to Other Party		$ 320,638
Subsequent Event [Member]
Litigation Settlement, Amount Awarded to Other Party, Number of Monthly Installments	9
Litigation Settlement, Amount Awarded to Other Party, Monthly Installments	$ 149,996